



Anylam Pharmaceuticals, Inc.  
Investor Relations Department  
300 Third Street  
Cambridge, MA 02142  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: ALNY 1

Last Trade:	81.76
Trade Time:	1:08 PM ET 07.28.2017
Change:	2.06  (2.585%)
Day Range	78.76 - 82.17
52-Week Range	31.38 - 86.92
Volume	227,786
Market Cap. (\$M)	7,480.222
Shares Out (M)	91.490

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Anylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics in three strategic therapeutic areas (STArS): genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases. These novel therapeutics carry the potential to transform the lives of patients who have limited or inadequate treatment options. Founded in 2002, Anylam is delivering on a bold vision to turn scientific possibility into a reality, with a robust discovery platform and deep pipeline of investigational medicines, including three product candidates that are i ... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- 07.27.2017 [Alylam to Host Fourth Annual "RNAi Roundtable" Webcast Series](#)
- 07.10.2017 [Alylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors](#)
- 07.07.2017 [Alylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors](#)
- 06.26.2017 [Alylam and Sanofi Genzyme to Present New Clinical Trial Results at the International Society of Thrombosis and Haemostasis \(ISTH\) Congress](#)
- 06.26.2017 [Alylam Reports New Positive Clinical Results for Givosiran \(ALN-AS1\), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias](#)

## Events [\[ View all \]](#)

- 08.03.2017 10:30 AM ET [2017 RNAi Roundtable: Patisiran, in development for the treatment of hereditary ATTR](#)
- 08.09.2017 12:30 PM ET [2017 RNAi Roundtable: Revusiran investigation results](#)
- 02.15.2017 [Annual Report \(10-K\)](#)
- 03.17.2017 [Definitive Proxy Statement](#)
- 05.05.2017 [Quarterly Report \(10-Q\)](#)
- 11.03.2016 [Quarterly Report \(10-Q\)](#)
- 08.04.2016 [Quarterly Report \(10-Q\)](#)

## Financials [\[ View all \]](#)

### [First Quarter Financial Results](#)

